Treats hypertension. ANDA 90083, held by Aurobindo Pharma. Losartan Potassium.
As of Nov 21, 2026, ANDA 90083 (Losartan Potassium), held by Aurobindo Pharma, was first approved by FDA on Oct 6, 2010, with 11 approved supplements and 0 published complete response letters.
Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2010 | Original application | Approved | None posted |
| Losartan Potassium25MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium50MG · tablet;oral | Losartan Potassium | Rx |
| Losartan Potassium100MG · tablet;oral | Losartan Potassium | Rx |
| Sep 9, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Jul 1, 2022 | Supplement 31Labeling · Standard review | Approved | None posted |
| Oct 21, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jun 10, 2016 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jul 7, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Sep 21, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 11, 2013 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 20, 2012 | Supplement 3Labeling | Approved | None posted |
| Dec 20, 2012 | Supplement 5Labeling | Approved | None posted |
| Dec 20, 2012 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 22, 2010 | Supplement 1Labeling | Approved | None posted |
| Oct 6, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters